Feng-Cai Zhu (Fengcai Zhu)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 19

Top Venues

Emerging microbes & infections

Human vaccines & immunotherapeutics

Nature medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu
Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19. Human vaccines & immunotherapeutics 19 (2) (2023)
Xiaoyin Zhang, Jiayue Xia, Lairun Jin, Yanfei Wu, Xiuyu Zheng, Xiang Cao, Xingchen Meng, Jingxin Li, Feng-Cai Zhu
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis. Human vaccines & immunotherapeutics 19 (2) (2023)
Pengfei Jin, Xiling Guo, Wei Chen, Shihua Ma, Hongxing Pan, Lianpan Dai, Pan Du, Lili Wang, Lai-Run Jin, Yin Chen, Fengjuan Shi, Jingxian Liu, Xiaoyu Xu, Yanan Zhang, George Fu Gao, Cancan Chen, Jialu Feng, Jingxin Li, Feng-Cai Zhu
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS medicine 19 (5) (2022)
Liguo Zhu, Naiying Mao, Changhua Yi, Aidibai Simayi, Jialu Feng, Yi Feng, Min He, Songning Ding, Yin Wang, Yan Wang, Mingwei Wei, Jie Hong, Chuchu Li, Hua Tian, Lu Zhou, Jiefu Peng, Shihan Zhang, Ci Song, Hui Jin, Feng-Cai Zhu, Wenbo Xu, Jun Zhao, Changjun Bao
Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by Serum live neutralization test based on a prospective cohort. Emerging microbes & infections (2022)
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin Chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Wei Chen, Jingxin Li, Feng-Cai Zhu
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerging microbes & infections 12 (1) (2022)
Lairun Jin, Zhuopei Li, Xiaoyin Zhang, Jingxin Li, Feng-Cai Zhu
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Human vaccines & immunotherapeutics (2022)
Jiaying Zhong, Shuo Liu, Tingting Cui, Jingxin Li, Feng-Cai Zhu, Nanshan Zhong, Wei Jin Huang, Zhuxiang Zhao, Zhongfang Wang
Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants. Emerging microbes & infections 11 (1) (2022)
Jinhua Chen, Pengfei Jin, Xiaoqi Chen, Qunying Mao, Fanyue Meng, Xinguo Li, Wei Chen, Meizhi Du, Fan Gao, Pei Liu, Xiujuan Li, Changfu Guo, Tingbo Xie, Weiwei Lu, Qingliang Li, Li Li, Xing Yan, Xiang Guo, Hongqiao Du, Xiuling Li, Kai Duan, Feng-Cai Zhu
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial. Human vaccines & immunotherapeutics 18 (5) (2022)
Hu-Dachuan Jiang, Xi-Ling Guo, Peng-Fei Jin, Rong Tang, Jing-Xin Li, Feng-Cai Zhu
Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens. Emerging microbes & infections 11 (1) (2022)
Zhuo-Pei Li, Yun-Feng Shi, Li-Hua Hou, Peng-Fei Jin, Shi-Hua Ma, Hong-Xing Pan, Jin-Long Zhang, Yong-Mei Shan, Hai-Tao Huang, Shi-Po Wu, Pan Du, Xue Wang, Li-Li Wang, Rui-Jie Wang, Ying Wang, Xue-Wen Wang, Feng-Cai Zhu, Jing-Xin Li
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. Expert review of vaccines 21 (12) (2022)
Li Zhang, Pengfei Jin, Mingwei Wei, Hudachuan Jiang, Jingxin Li, Feng-Cai Zhu
A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial. Human vaccines & immunotherapeutics 18 (5) (2022)
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin Chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Wei Chen, Jingxin Li, Feng-Cai Zhu
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerging microbes & infections 12 (1) (2022)
Jingxin Li, Ai-Min Hui, Xiang Zhang, Lei Ge, Yuanzheng Qiu, Rong Tang, Huayue Ye, Xiyuan Wang, Mei Lin, Zhongkui Zhu, Jianfei Zheng, Jingjun Qiu, Eleni Lagkadinou, Svetlana Shpyro, Orkun Ozhelvaci, Özlem Türeci, Zakaria Khondker, Wanrong Yin, Yoana Shishkova, Siyue Jia, Hongxing Pan, Fuzhong Peng, Zhilong Ma, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Alexander Muik, Uğur Şahin, Li Zhu, Feng-Cai Zhu
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Advances in therapy 39 (8) (2022)
Jingxin Li, Li-Hua Hou, Xiling Guo, Pengfei Jin, Shipo Wu, Jiahong Zhu, Hongxing Pan, Xue Wang, Zhizhou Song, Jingxuan Wan, Lunbiao Cui, Junqiang Li, Yin Chen, Xuewen Wang, Lairun Jin, Jingxian Liu, Fengjuan Shi, Xiaoyu Xu, Tao Zhu, Wei Chen, Feng-Cai Zhu
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nature medicine 28 (2) (2022)
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang, Lihua Hou, Xiaoqin Chen, Tao Zhu, Jinbo Gou, Jin Zhong, Hongxing Pan, Lunbiao Cui, Yin Chen, Xin Xia, Jialu Feng, Xue Wang, Qi Zhao, XiaoYu Xu, Zhuopei Li, Xiaoyin Zhang, Wei Chen, Jingxin Li, Feng-Cai Zhu
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: twelve-month analyses of a randomized controlled trial. Emerging microbes & infections (2022)
Jingxin Li, Ai-Min Hui, Xiang Zhang, Yumei Yang, Rong Tang, Huayue Ye, Ruiru Ji, Mei Lin, Zhongkui Zhu, Özlem Türeci, Eleni Lagkadinou, Siyue Jia, Hongxing Pan, Fuzhong Peng, Zhilong Ma, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Alexander Muik, Uğur Şahin, Li Zhu, Feng-Cai Zhu
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature medicine 27 (6) (2021)
Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo, Jia-Lu Zhang, Bo-Pei Cui, Zhi-Ming Wu, Ming-Wei Wei, Zhi-Long Ma, Hai-Lin Peng, Hong-Xing Pan, Lin Fan, Jing Zhang, Jiu-Qin Wan, Zhong-Kui Zhu, Xue-Wen Wang, Feng-Cai Zhu
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal transduction and targeted therapy 6 (1) (2021)
Kang Wang, Binyang Zheng, Li Zhang, Lunbiao Cui, Xuan Su, Qian Zhang, Zhenxi Guo, Yu Guo, Wei Zhang, Ling Zhu, Feng-Cai Zhu, Zihe Rao, Xiangxi Wang
Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B. Nature communications 11 (1) (2020)
Kang Wang, Ling Zhu, Yao Sun, Minhao Li, Xin Zhao, Lunbiao Cui, Li Zhang, George Fu Gao, Weiwei Zhai, Feng-Cai Zhu, Zihe Rao, Xiangxi Wang
Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage. Nature communications 11 (1) (2020)

Feng-Cai Zhu.css-eqlu8i{font-size:small;padding-left:4px;} (Fengcai Zhu)

Publication Activity (10 Years)

Top Topics

Top Venues

Feng-Cai Zhu (Fengcai Zhu)